Alumis (ALMS) vs Adlai Nortye Group (ANL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Alumis (ALMS) over the past year, gaining 712.1% versus a gain of 50.1%. Adlai Nortye Group is the larger company by market cap ($998.8 million vs $902.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | ANL |
|---|---|---|
| Share price | $6.97 | $15.51 |
| Market cap | $902.16M | $998.81M |
| 1-day change | +2.95% | +10.39% |
| YTD return | -30.64% | +889.44% |
| 1-year return | +50.11% | +712.14% |
| EPS (TTM) | $-3.86 | $-0.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $17.25 |
| 52-week low | $4.28 | $0.879 |
| Distance from 52-week high | -77.77% | -10.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +360.98% | +90.20% |
| Average volume | 2.43M | 175.26K |
| Shares outstanding | 129.44M | 58.73M |
| Employees | 237 | 109 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed ALMS by 662.0 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
ALMS vs ANL FAQ
Which is bigger, Alumis or Adlai Nortye Group?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $998.81M compared with $902.16M for Alumis (ALMS).
Which stock has performed better over the past year, ALMS or ANL?
ANL returned +712.14% over the past 12 months, compared with +50.11% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Adlai Nortye Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.